Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 12 entries
Sorted by: Best Match Show Resources per page
Electrochemical reduction of nicergoline and its analytical determination in dosage forms.

Talanta

Sturm JC, Nunez-Vergara LJ, Squella JA.
PMID: 18965506
Talanta. 1992 Sep;39(9):1149-54. doi: 10.1016/0039-9140(92)80213-w.

Electrochemical reduction of nicergoline was studied at different pH and concentrations using differential pulse polarography and linear sweep voltammetry. Both techniques reveal that the reduction process occurs with strong adsorption of the product. Nicergoline is an excellent model for...

Cite
Sturm JC, Nunez-Vergara LJ, Squella JA. Electrochemical reduction of nicergoline and its analytical determination in dosage forms. Talanta. 1992;39(9):1149-54doi: 10.1016/0039-9140(92)80213-w.
Sturm, J. C., Nunez-Vergara, L. J., & Squella, J. A. (1992). Electrochemical reduction of nicergoline and its analytical determination in dosage forms. Talanta, 39(9), 1149-54. https://doi.org/10.1016/0039-9140(92)80213-w
Sturm, J C, et al. "Electrochemical reduction of nicergoline and its analytical determination in dosage forms." Talanta vol. 39,9 (1992): 1149-54. doi: https://doi.org/10.1016/0039-9140(92)80213-w
Sturm JC, Nunez-Vergara LJ, Squella JA. Electrochemical reduction of nicergoline and its analytical determination in dosage forms. Talanta. 1992 Sep;39(9):1149-54. doi: 10.1016/0039-9140(92)80213-w. PMID: 18965506.
Copy Download .nbib Format: NLM
Phosphodiesterase Inhibitors for Alzheimer's Disease: A Systematic Review of Clinical Trials and Epidemiology with a Mechanistic Rationale.

Journal of Alzheimer's disease reports

Sanders O, Rajagopal L.
PMID: 32715279
J Alzheimers Dis Rep. 2020 Jun 16;4(1):185-215. doi: 10.3233/ADR-200191.

BACKGROUND: Preclinical studies, clinical trials, and reviews suggest increasing 3',5'-cyclic adenosine monophosphate (cAMP) and 3',5'-cyclic guanosine monophosphate (cGMP) with phosphodiesterase inhibitors is disease-modifying in Alzheimer's disease (AD). cAMP/protein kinase A (PKA) and cGMP/protein kinase G (PKG) signaling are disrupted...

Cite
Sanders O, Rajagopal L. Phosphodiesterase Inhibitors for Alzheimer's Disease: A Systematic Review of Clinical Trials and Epidemiology with a Mechanistic Rationale. J Alzheimers Dis Rep. 2020;4(1):185-215doi: 10.3233/ADR-200191.
Sanders, O., & Rajagopal, L. (2020). Phosphodiesterase Inhibitors for Alzheimer's Disease: A Systematic Review of Clinical Trials and Epidemiology with a Mechanistic Rationale. Journal of Alzheimer's disease reports, 4(1), 185-215. https://doi.org/10.3233/ADR-200191
Sanders, Owen, and Rajagopal, Lekshmy. "Phosphodiesterase Inhibitors for Alzheimer's Disease: A Systematic Review of Clinical Trials and Epidemiology with a Mechanistic Rationale." Journal of Alzheimer's disease reports vol. 4,1 (2020): 185-215. doi: https://doi.org/10.3233/ADR-200191
Sanders O, Rajagopal L. Phosphodiesterase Inhibitors for Alzheimer's Disease: A Systematic Review of Clinical Trials and Epidemiology with a Mechanistic Rationale. J Alzheimers Dis Rep. 2020 Jun 16;4(1):185-215. doi: 10.3233/ADR-200191. PMID: 32715279; PMCID: PMC7369141.
Copy Download .nbib Format: NLM
Cholinergic deficits in aged rat brain are corrected with nicergoline.

Archives of gerontology and geriatrics

Ogawa N, Asanuma M, Hirata H, Kondo Y, Kawada Y, Mori A.
PMID: 15374340
Arch Gerontol Geriatr. 1993 Mar-Apr;16(2):103-10. doi: 10.1016/0167-4943(93)90001-x.

Choline acetyltransferase (CAT) and muscarinic cholinergic receptor (MCR) activities are markedly reduced in aged as compared with young-adult rat brain. Nicergoline was found to correct these reduced activities in most regions of the brain, especially in the cerebral cortex...

Cite
Ogawa N, Asanuma M, Hirata H, et al. Cholinergic deficits in aged rat brain are corrected with nicergoline. Arch Gerontol Geriatr. 1993;16(2):103-10doi: 10.1016/0167-4943(93)90001-x.
Ogawa, N., Asanuma, M., Hirata, H., Kondo, Y., Kawada, Y., & Mori, A. (1993). Cholinergic deficits in aged rat brain are corrected with nicergoline. Archives of gerontology and geriatrics, 16(2), 103-10. https://doi.org/10.1016/0167-4943(93)90001-x
Ogawa, N, et al. "Cholinergic deficits in aged rat brain are corrected with nicergoline." Archives of gerontology and geriatrics vol. 16,2 (1993): 103-10. doi: https://doi.org/10.1016/0167-4943(93)90001-x
Ogawa N, Asanuma M, Hirata H, Kondo Y, Kawada Y, Mori A. Cholinergic deficits in aged rat brain are corrected with nicergoline. Arch Gerontol Geriatr. 1993 Mar-Apr;16(2):103-10. doi: 10.1016/0167-4943(93)90001-x. PMID: 15374340.
Copy Download .nbib Format: NLM
Sesame Oil-Based Nanostructured Lipid Carriers of Nicergoline, Intranasal Delivery System for Brain Targeting of Synergistic Cerebrovascular Protection.

Pharmaceutics

Abourehab MAS, Khames A, Genedy S, Mostafa S, Khaleel MA, Omar MM, El Sisi AM.
PMID: 33921796
Pharmaceutics. 2021 Apr 19;13(4). doi: 10.3390/pharmaceutics13040581.

Nicergoline (NIC) is a semisynthetic ergot alkaloid derivative applied for treatment of dementia and other cerebrovascular disorders. The efficacy of sesame oil to slow and reverse the symptoms of neurodegenerative cognitive disorders has been proven. This work aimed to...

Cite
Abourehab MAS, Khames A, Genedy S, et al. Sesame Oil-Based Nanostructured Lipid Carriers of Nicergoline, Intranasal Delivery System for Brain Targeting of Synergistic Cerebrovascular Protection. Pharmaceutics. 2021;13(4)doi: 10.3390/pharmaceutics13040581.
Abourehab, M. A. S., Khames, A., Genedy, S., Mostafa, S., Khaleel, M. A., Omar, M. M., & El Sisi, A. M. (2021). Sesame Oil-Based Nanostructured Lipid Carriers of Nicergoline, Intranasal Delivery System for Brain Targeting of Synergistic Cerebrovascular Protection. Pharmaceutics, 13(4), . https://doi.org/10.3390/pharmaceutics13040581
Abourehab, Mohammed A S, et al. "Sesame Oil-Based Nanostructured Lipid Carriers of Nicergoline, Intranasal Delivery System for Brain Targeting of Synergistic Cerebrovascular Protection." Pharmaceutics vol. 13,4 (2021). doi: https://doi.org/10.3390/pharmaceutics13040581
Abourehab MAS, Khames A, Genedy S, Mostafa S, Khaleel MA, Omar MM, El Sisi AM. Sesame Oil-Based Nanostructured Lipid Carriers of Nicergoline, Intranasal Delivery System for Brain Targeting of Synergistic Cerebrovascular Protection. Pharmaceutics. 2021 Apr 19;13(4). doi: 10.3390/pharmaceutics13040581. PMID: 33921796; PMCID: PMC8072759.
Copy Download .nbib Format: NLM
Dysthymia and apathy: diagnosis and treatment.

Depression research and treatment

Ishizaki J, Mimura M.
PMID: 21747995
Depress Res Treat. 2011;2011:893905. doi: 10.1155/2011/893905. Epub 2011 Jun 27.

Dysthymia is a depressive mood disorder characterized by chronic and persistent but mild depression. It is often difficult to be distinguished from major depression, specifically in its partially remitted state because "loss of interest" or "apathy" tends to prevail...

Cite
Ishizaki J, Mimura M. Dysthymia and apathy: diagnosis and treatment. Depress Res Treat. 2011;2011:893905doi: 10.1155/2011/893905.
Ishizaki, J., & Mimura, M. (2011). Dysthymia and apathy: diagnosis and treatment. Depression research and treatment, 2011893905. https://doi.org/10.1155/2011/893905
Ishizaki, Junko, and Mimura, Masaru. "Dysthymia and apathy: diagnosis and treatment." Depression research and treatment vol. 2011 (2011): 893905. doi: https://doi.org/10.1155/2011/893905
Ishizaki J, Mimura M. Dysthymia and apathy: diagnosis and treatment. Depress Res Treat. 2011;2011:893905. doi: 10.1155/2011/893905. Epub 2011 Jun 27. PMID: 21747995; PMCID: PMC3130974.
Copy Download .nbib Format: NLM
Long-Term Nicergoline Treatment of Mild to Moderate Senile Dementia : Results of a Multicentre, Double-Blind, Placebo-Controlled Study.

Clinical drug investigation

Nappi G, Bono G, Merlo P, Borromei A, Caltagirone C, Lomeo C, Martucci N, Fabbrini G, Annoni K, Battaglia A.
PMID: 27519492
Clin Drug Investig. 1997 Jun;13(6):308-16. doi: 10.2165/00044011-199713060-00003.

The efficacy and tolerability of nicergoline were evaluated in a long-term, double-blind, placebo-controlled trial. 108 patients, fulfilling DSM III-R criteria for mild to moderate senile dementia of degenerative, vascular or mixed origin, were selected from a pool of outpatients...

Cite
Nappi G, Bono G, Merlo P, et al. Long-Term Nicergoline Treatment of Mild to Moderate Senile Dementia : Results of a Multicentre, Double-Blind, Placebo-Controlled Study. Clin Drug Investig. 1997;13(6):308-16doi: 10.2165/00044011-199713060-00003.
Nappi, G., Bono, G., Merlo, P., Borromei, A., Caltagirone, C., Lomeo, C., Martucci, N., Fabbrini, G., Annoni, K., & Battaglia, A. (1997). Long-Term Nicergoline Treatment of Mild to Moderate Senile Dementia : Results of a Multicentre, Double-Blind, Placebo-Controlled Study. Clinical drug investigation, 13(6), 308-16. https://doi.org/10.2165/00044011-199713060-00003
Nappi, G, et al. "Long-Term Nicergoline Treatment of Mild to Moderate Senile Dementia : Results of a Multicentre, Double-Blind, Placebo-Controlled Study." Clinical drug investigation vol. 13,6 (1997): 308-16. doi: https://doi.org/10.2165/00044011-199713060-00003
Nappi G, Bono G, Merlo P, Borromei A, Caltagirone C, Lomeo C, Martucci N, Fabbrini G, Annoni K, Battaglia A. Long-Term Nicergoline Treatment of Mild to Moderate Senile Dementia : Results of a Multicentre, Double-Blind, Placebo-Controlled Study. Clin Drug Investig. 1997 Jun;13(6):308-16. doi: 10.2165/00044011-199713060-00003. PMID: 27519492.
Copy Download .nbib Format: NLM
Alteration in plasma and striatal levels of d-serine after d-serine administration with or without nicergoline: An .

Heliyon

Onozato M, Nakazawa H, Ishimaru K, Nagashima C, Fukumoto M, Hakariya H, Sakamoto T, Ichiba H, Fukushima T.
PMID: 28924620
Heliyon. 2017 Sep 06;3(9):e00399. doi: 10.1016/j.heliyon.2017.e00399. eCollection 2017 Sep.

AIMS: d-Serine (d-Ser), a co-agonist of MAIN METHODS: Phosphate-buffered saline (PBS) or Nic (0, 1.0, or 3.0 mg/kg) followed by d-Ser (5.0, 10.0, 20.0, and 50.0 mg/kg for PBS or 20.0 mg/kg for Nic) was administered intraperitoneally to male...

Cite
Onozato M, Nakazawa H, Ishimaru K, et al. Alteration in plasma and striatal levels of d-serine after d-serine administration with or without nicergoline: An . Heliyon. 2017;3(9):e00399doi: 10.1016/j.heliyon.2017.e00399.
Onozato, M., Nakazawa, H., Ishimaru, K., Nagashima, C., Fukumoto, M., Hakariya, H., Sakamoto, T., Ichiba, H., & Fukushima, T. (2017). Alteration in plasma and striatal levels of d-serine after d-serine administration with or without nicergoline: An . Heliyon, 3(9), e00399. https://doi.org/10.1016/j.heliyon.2017.e00399
Onozato, Mayu, et al. "Alteration in plasma and striatal levels of d-serine after d-serine administration with or without nicergoline: An ." Heliyon vol. 3,9 (2017): e00399. doi: https://doi.org/10.1016/j.heliyon.2017.e00399
Onozato M, Nakazawa H, Ishimaru K, Nagashima C, Fukumoto M, Hakariya H, Sakamoto T, Ichiba H, Fukushima T. Alteration in plasma and striatal levels of d-serine after d-serine administration with or without nicergoline: An . Heliyon. 2017 Sep 06;3(9):e00399. doi: 10.1016/j.heliyon.2017.e00399. eCollection 2017 Sep. PMID: 28924620; PMCID: PMC5591394.
Copy Download .nbib Format: NLM
Changes in Regional Cerebral Perfusion after Nicergoline Treatment in Early Alzheimer's Disease: A Pilot Study.

Dementia and neurocognitive disorders

Im JJ, Jeong HS, Park JS, Yang Y, Na SH, Oh JK, Chung YA, Song IU.
PMID: 30906380
Dement Neurocogn Disord. 2017 Dec;16(4):104-109. doi: 10.12779/dnd.2017.16.4.104. Epub 2017 Dec 31.

BACKGROUND AND PURPOSE: Nicergoline is an ergoline derivative that is used to treat cognitive deficits in cerebrovascular disease and various forms of dementia. Although therapeutic effects of nicergoline have been established, little is known about its effects on cerebral...

Cite
Im JJ, Jeong HS, Park JS, et al. Changes in Regional Cerebral Perfusion after Nicergoline Treatment in Early Alzheimer's Disease: A Pilot Study. Dement Neurocogn Disord. 2017;16(4):104-109doi: 10.12779/dnd.2017.16.4.104.
Im, J. J., Jeong, H. S., Park, J. S., Yang, Y., Na, S. H., Oh, J. K., Chung, Y. A., & Song, I. U. (2017). Changes in Regional Cerebral Perfusion after Nicergoline Treatment in Early Alzheimer's Disease: A Pilot Study. Dementia and neurocognitive disorders, 16(4), 104-109. https://doi.org/10.12779/dnd.2017.16.4.104
Im, Jooyeon J, et al. "Changes in Regional Cerebral Perfusion after Nicergoline Treatment in Early Alzheimer's Disease: A Pilot Study." Dementia and neurocognitive disorders vol. 16,4 (2017): 104-109. doi: https://doi.org/10.12779/dnd.2017.16.4.104
Im JJ, Jeong HS, Park JS, Yang Y, Na SH, Oh JK, Chung YA, Song IU. Changes in Regional Cerebral Perfusion after Nicergoline Treatment in Early Alzheimer's Disease: A Pilot Study. Dement Neurocogn Disord. 2017 Dec;16(4):104-109. doi: 10.12779/dnd.2017.16.4.104. Epub 2017 Dec 31. PMID: 30906380; PMCID: PMC6428003.
Copy Download .nbib Format: NLM
Use of Nicergoline as Adjunctive Treatment of Neurotrophic Keratitis in Routine Clinical Practice: A Case Series.

Ocular immunology and inflammation

Miguel-Escuder L, Rocha-de-Lossada C, Sabater-Cruz N, Sánchez-González JM, Spencer F, Marín-Martínez S, Batlle-Ferrando S, Carreras Castañer X, Torras J, Peraza-Nieves J.
PMID: 34637676
Ocul Immunol Inflamm. 2021 Oct 12;1-5. doi: 10.1080/09273948.2021.1976214. Epub 2021 Oct 12.

PURPOSE: To describe the effectiveness and safety of nicergoline in patients with epithelial corneal defect or corneal ulcer due to neurotrophic keratitis (NK).METHODS: A prospective case series review was performed in 14 patients with NK who started treatment with...

Cite
Miguel-Escuder L, Rocha-de-Lossada C, Sabater-Cruz N, et al. Use of Nicergoline as Adjunctive Treatment of Neurotrophic Keratitis in Routine Clinical Practice: A Case Series. Ocul Immunol Inflamm. 2021;1-5doi: 10.1080/09273948.2021.1976214.
Miguel-Escuder, L., Rocha-de-Lossada, C., Sabater-Cruz, N., Sánchez-González, J. M., Spencer, F., Marín-Martínez, S., Batlle-Ferrando, S., Carreras Castañer, X., Torras, J., & Peraza-Nieves, J. (2021). Use of Nicergoline as Adjunctive Treatment of Neurotrophic Keratitis in Routine Clinical Practice: A Case Series. Ocular immunology and inflammation, 1-5. https://doi.org/10.1080/09273948.2021.1976214
Miguel-Escuder, L, et al. "Use of Nicergoline as Adjunctive Treatment of Neurotrophic Keratitis in Routine Clinical Practice: A Case Series." Ocular immunology and inflammation vol. (2021): 1-5. doi: https://doi.org/10.1080/09273948.2021.1976214
Miguel-Escuder L, Rocha-de-Lossada C, Sabater-Cruz N, Sánchez-González JM, Spencer F, Marín-Martínez S, Batlle-Ferrando S, Carreras Castañer X, Torras J, Peraza-Nieves J. Use of Nicergoline as Adjunctive Treatment of Neurotrophic Keratitis in Routine Clinical Practice: A Case Series. Ocul Immunol Inflamm. 2021 Oct 12;1-5. doi: 10.1080/09273948.2021.1976214. Epub 2021 Oct 12. PMID: 34637676.
Copy Download .nbib Format: NLM
[Efficacy of Sermion in the treatment of tinnitus noise in patients with chronic cerebrovascular pathology].

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova

Ekusheva EV.
PMID: 34874656
Zh Nevrol Psikhiatr Im S S Korsakova. 2021;121(10):60-66. doi: 10.17116/jnevro202112110160.

Noise in the ears or tinnitus is one of the earliest and most frequent non-cognitive manifestations of chronic cerebral ischemia (CCI) and is the most difficult clinical phenomenon for therapeutic intervention.OBJECTIVE: Of an open observational noncomparative clinical study was...

Cite
Ekusheva EV. Effektivnost' Sermiona v lechenii shuma v ushakh u patsientov s khronicheskoi tserebrovaskulyarnoi patologiei. [Efficacy of Sermion in the treatment of tinnitus noise in patients with chronic cerebrovascular pathology]. Zh Nevrol Psikhiatr Im S S Korsakova. 2021;121(10):60-66doi: 10.17116/jnevro202112110160.
Ekusheva, E. V. (2021). Effektivnost' Sermiona v lechenii shuma v ushakh u patsientov s khronicheskoi tserebrovaskulyarnoi patologiei. [Efficacy of Sermion in the treatment of tinnitus noise in patients with chronic cerebrovascular pathology]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 121(10), 60-66. https://doi.org/10.17116/jnevro202112110160
Ekusheva, E V. "Effektivnost' Sermiona v lechenii shuma v ushakh u patsientov s khronicheskoi tserebrovaskulyarnoi patologiei." [Efficacy of Sermion in the treatment of tinnitus noise in patients with chronic cerebrovascular pathology]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova vol. 121,10 (2021): 60-66. doi: https://doi.org/10.17116/jnevro202112110160
Ekusheva EV. Effektivnost' Sermiona v lechenii shuma v ushakh u patsientov s khronicheskoi tserebrovaskulyarnoi patologiei. [Efficacy of Sermion in the treatment of tinnitus noise in patients with chronic cerebrovascular pathology]. Zh Nevrol Psikhiatr Im S S Korsakova. 2021;121(10):60-66. doi: 10.17116/jnevro202112110160. Russian. PMID: 34874656.
Copy Download .nbib Format: NLM
The Morphological and Dynamic Changes of Ultrasound in the Evaluation of Effects of Oral Steroids Treatment for Patients with Carpal Tunnel Syndrome.

Diagnostics (Basel, Switzerland)

Yau YC, Yang CP, Lin CP, Tsai IJ, Chang CM, Yang CC, Shih PH, Liao YY.
PMID: 34441271
Diagnostics (Basel). 2021 Jul 26;11(8). doi: 10.3390/diagnostics11081336.

The role of oral steroids in carpal tunnel syndrome (CTS) remains elusive. This study aims to depict the ultrasound findings and conceivable mechanisms in relation to the efficacy of oral steroids for patients with CTS by measuring the morphological...

Cite
Yau YC, Yang CP, Lin CP, et al. The Morphological and Dynamic Changes of Ultrasound in the Evaluation of Effects of Oral Steroids Treatment for Patients with Carpal Tunnel Syndrome. Diagnostics (Basel). 2021;11(8)doi: 10.3390/diagnostics11081336.
Yau, Y. C., Yang, C. P., Lin, C. P., Tsai, I. J., Chang, C. M., Yang, C. C., Shih, P. H., & Liao, Y. Y. (2021). The Morphological and Dynamic Changes of Ultrasound in the Evaluation of Effects of Oral Steroids Treatment for Patients with Carpal Tunnel Syndrome. Diagnostics (Basel, Switzerland), 11(8), . https://doi.org/10.3390/diagnostics11081336
Yau, Yun-Chain, et al. "The Morphological and Dynamic Changes of Ultrasound in the Evaluation of Effects of Oral Steroids Treatment for Patients with Carpal Tunnel Syndrome." Diagnostics (Basel, Switzerland) vol. 11,8 (2021). doi: https://doi.org/10.3390/diagnostics11081336
Yau YC, Yang CP, Lin CP, Tsai IJ, Chang CM, Yang CC, Shih PH, Liao YY. The Morphological and Dynamic Changes of Ultrasound in the Evaluation of Effects of Oral Steroids Treatment for Patients with Carpal Tunnel Syndrome. Diagnostics (Basel). 2021 Jul 26;11(8). doi: 10.3390/diagnostics11081336. PMID: 34441271; PMCID: PMC8391183.
Copy Download .nbib Format: NLM
Determination of metabolite of nicergoline in human plasma by high-performance liquid chromatography and its application in pharmacokinetic studies.

Journal of pharmaceutical analysis

Zheng R, Wu YH, Jiang DX, Zhang D.
PMID: 29403722
J Pharm Anal. 2012 Feb;2(1):62-66. doi: 10.1016/j.jpha.2011.09.005. Epub 2012 Jan 04.

A fast, simple and sensitive high performance liquid chromatographic (HPLC) method has been developed for determination of 10

Cite
Zheng R, Wu YH, Jiang DX, et al. Determination of metabolite of nicergoline in human plasma by high-performance liquid chromatography and its application in pharmacokinetic studies. J Pharm Anal. 2012;2(1):62-66doi: 10.1016/j.jpha.2011.09.005.
Zheng, R., Wu, Y. H., Jiang, D. X., & Zhang, D. (2012). Determination of metabolite of nicergoline in human plasma by high-performance liquid chromatography and its application in pharmacokinetic studies. Journal of pharmaceutical analysis, 2(1), 62-66. https://doi.org/10.1016/j.jpha.2011.09.005
Zheng, Rong, et al. "Determination of metabolite of nicergoline in human plasma by high-performance liquid chromatography and its application in pharmacokinetic studies." Journal of pharmaceutical analysis vol. 2,1 (2012): 62-66. doi: https://doi.org/10.1016/j.jpha.2011.09.005
Zheng R, Wu YH, Jiang DX, Zhang D. Determination of metabolite of nicergoline in human plasma by high-performance liquid chromatography and its application in pharmacokinetic studies. J Pharm Anal. 2012 Feb;2(1):62-66. doi: 10.1016/j.jpha.2011.09.005. Epub 2012 Jan 04. PMID: 29403722; PMCID: PMC5760819.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 12 entries